Vertaling van "parkinson's diseases nice " (Frans → Nederlands) :

The 12th International Conference on Alzheimer's and Parkinson's Diseases (Nice - France, 18-22 Mars 2015) kenes-group.com
The 12th International Conference on Alzheimer's and Parkinson's Diseases (Nice - France, 18-22 maart 2015) kenes-group.com

10th International Congress on Mental Dysfunction & Other Non-Motor Features in Parkinson's Disease and Related Disorders (MDPD 2014) (Nice - France, 04-07 Décembre 2014) kenes-group.com
10th International Congress on Mental Dysfunction & Other Non-Motor Features in Parkinson's Disease and Related Disorders (MDPD 2014) (Nice - France, 04-07 december 2014) kenes-group.com

10th International Congress on Mental Dysfunction & Other Non-Motor Features in Parkinson's Disease and Related Disorders (Nice - France, 29 Mai - 01 Juin 2014) kenes-group.com
10th International Congress on Mental Dysfunction & Other Non-Motor Features in Parkinson's Disease and Related Disorders (Nice - France, 29 mei - 01 juni 2014) kenes-group.com

Source Statement ACA Not included ACP Not included ASA Selected patients : Agreement : 90 % of consultants, 92 % ASA Members To consider : smoking, recent infection, COPD, and cardiac disease ICSI Selected patients with signs or symptoms suggesting new or unstable cardiopulmonary disease INAHTA Chest X-ray abnormality correspond more closely with ASA status than with age (McCleane) i The results of between 0% and 2.1% of chest X-rays leads to a change in management There is no published evidence that routine preoperative chest X-rays decrease perioperative risks ii . NICE Minor surgery: ASA I : not indicated ASA II : consider > 40 y if respiratory or CV disease ASA III : consider if respiratory or CV disease Intermediate surgery: ASA I : not indicated ASA II : consider if respiratory or CV disease (renal > 60y) ASA III : consider if respiratory, CV or renal disease Major surgery: ASA I : consider > 60 ASA II : consider if respiratory, CV or renal disease ASA III : consider if respiratory, CV or renal disease
Source Statement ACA Not included ACP Not included ASA Selected patients : Agreement : 90 % of consultants, 92 % ASA Members To consider : smoking, recent infection, COPD, and cardiac disease ICSI Selected patients with signs or symptoms suggesting new or unstable cardiopulmonary disease INAHTA Chest X-ray abnormality correspond more closely with ASA status than with age (McCleane) i The results of between 0% and 2.1% of chest X-rays leads to a change in management There is no published evidence that routine preoperative chest X-rays decrease

XX WFN World Congress on Parkinson's Disease and Related Disorders (Geneva - Switzerland, 08-11 Décembre 2013) kenes.com
XX WFN World Congress on Parkinson's Disease and Related Disorders (Geneva - Switzerland, 08-11 december 2013) kenes.com

D’après O. Rascol et al.: Treatment interventions for Parkinson’s disease: an evidence based assessment.
Naar O. Rascol et al.: Treatment interventions for Parkinson’s disease: an evidence based assessment.

Nakayama Y, Washiu M, Mori M. Oral health conditions in patients with Parkinson’s disease. J
Nakayama Y, Washiu M, Mori M. Oral health conditions in patients with Parkinson’s

folding and its platform for drug and target discovery, the company is building a pipeline, initially for neurodegenerative and respiratory conditions. FoldRx’s pipeline includes a program in advanced clinical development to treat genetic neurologic and cardiovascular disorders, Transthyretin (TTR) Amyloid Polyneuropathy (ATTR-PN) and TTR Amyloid Cardiomyopathy (ATTR-CM), and a discovery program in cystic fibrosis, Parkinson’s, and Huntington’s disease based on its broad, proprietary, yeast-based drug discovery platform.
FoldRx is a development and discovery company focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding and aggregation (amyloidosis) based on the pioneer work of its scientific founders, Jeffery Kelly (The Scripps Research Institute) and Susan Lindquist (Whitehead Institute).

O. Rascol et al.: Treatment interventions for Parkinson’s disease: an evidence based assessment. Lancet 359 : 1589-1598(2002)
O. Rascol et al.: Treatment interventions for Parkinson’s disease: an evidence based assessment Lancet 359 : 1589-1598(2002)